Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Prescription Drug Affordability Board briefs Finance Committee on cost reviews, WACC penalty and potential price limits
Summary
Dr. Andy York told the Finance Committee on Jan. 15 that the board has completed preliminary affordability determinations for two diabetes drugs and has recommended policy options — including an incentive to curb list‑price growth and plans to pursue upper payment limits — with final actions expected after public methodology review this spring.
Dr. Andy York, executive director of the Prescription Drug Affordability Board, told the Senate Finance Committee on Jan. 15 that the board has completed preliminary affordability determinations for two diabetes drugs and is preparing policy work and rulemaking that could lead to price limits for some prescription medicines.
"We are an independent state agency that's ... dedicated to making prescription drugs more affordable for Marylanders," York said, describing a five‑member board supported by a stakeholder council that expanded to 29 members. He walked lawmakers through the board's five‑step cost‑review process — data collection and outreach, dossier publication, board review and policy recommendations — and said staff will publish methodology and framework documents for public review before any final action.
The board has six drugs in its current cost‑review pipeline, York said: Farxiga and Jardiance (SGLT2 diabetes drugs), Ozempic and Trulicity (GLP‑1 diabetes drugs, studied here for diabetes indications), and Dupixent and Skyrizi (used for…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
